[
  {
    "id": "SRC001",
    "stem": "A 39-year-old BRCA2-positive woman undergoes prophylactic bilateral mastectomy with reconstruction. Pathology reveals an incidental 3 mm invasive ductal carcinoma, ER+, PR+, HER2\u2013, no lymphovascular invasion. What is the most appropriate management?",
    "choices": [
      "Adjuvant chemotherapy",
      "Postmastectomy radiation therapy",
      "Endocrine therapy alone",
      "Observation only"
    ],
    "answerIndex": 2,
    "rationale": "Tumor <5 mm, ER+/PR+, HER2\u2013, no high-risk features \u2192 low-risk profile. Endocrine therapy provides systemic benefit without need for chemo or radiation.",
    "wrongAnswerNotes": {
      "Adjuvant chemotherapy": "Overtreatment.",
      "Postmastectomy radiation therapy": "Not indicated with clear margins and negative nodes.",
      "Observation only": "No adjuvant therapy reduces recurrence risk."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "ER+",
      "Small invasive cancer",
      "Risk stratification"
    ]
  }
]